Therapeutic patents for topical and transdermal drug delivery systems

Bibliography

• WESTER RC, MAIBACH HI: Percutaneous absorption of drugs. Olin. Pharmacokinet. (1992) 23:253–266.
   PubMed Web of Science ®Google Scholar
• FINNIN BC, MORGAN TM: Transdermal penetration enhancers: applications, limitations and potential. J. Pharm. Sci. (1999) 88:955–958.
   PubMed Web of Science ®Google Scholar
• HADGRAFT J. Pharmaceutical aspects of transdermal nitroglycerin. Int. J. Pharm. (1996) 135:1–11
   Web of Science ®Google Scholar
• PALMER KJ, BUCKLEY MM, FAULD D: Transdermal nicotine: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy as an aid to smoking cessation. Drugs (1992) 44:498–529.
   PubMed Web of Science ®Google Scholar
• SHAH VP, FLYNN GL, YACOBI A et al. Bioequivalence of dermatological dosage forms-methods of of bioequivalence. Pharm. Res. (1998) 15:167–171.
   PubMed Web of Science ®Google Scholar
• FLYNN GL, SHAH VP, TENJARLA SN et al: Assessment ofvalue and applications of in vitro testing of topical dermatological drug products. Pharm. Res. (1999) 16(9):1325–1330.
   PubMed Web of Science ®Google Scholar
• GILBER P, JONES MV, ALLISON DG, HEYS S, MARIA T,WOOD P: The use of poloxamer hydrogels for the assessment of biofllm susceptibility toward biocide treatments. J Appl. Microbiol. (1998) 85(6)985–990.
   Google Scholar
• ANONYMOUS: Bromelain. Alternative Med. Rev. (1998)3 (4):302–305.
   Google Scholar
• LEE KL, ALBEE KL, BERNASCONI RJ, EDMUNDS T:Complete amino acid sequence of ananain and a comparison with stem bromelain and other plant cysteine proteases. Biochem. 1 (1997) 327(1):199–202.
   Google Scholar
• CASTELL JV, FRIEDRICH G, KUHN CS, POPPE GE:Intestinal absorption of undegraded proteins in men: presence of bromelain in plasma after oral intake. Am. Physiol. (1997) 273(1):139–146
   Web of Science ®Google Scholar
• MARGOLIUS HS: Kallikreins and kinins. Molecularcharacteristics and cellular and tissue responses. Diabetes (1996) 45\(Supp1.1):S14–19.
   Google Scholar
• UEHARA Y, HIRAWA N, NUMABE A et al. Long-term of kallikrein attenuates renal injury in Dahl salt-sensitive rats. Am. J. Hypertens. (1997) 10(5Pt 2) 83S–88S
   Google Scholar
• CHEN H, ZHANG ZS, ZHANG YL, ZHOU DY: Curcumininhibits cell proliferation by interfering with the cell cycle and inducing apoptosis in colon carcinoma cells. AntiCancer Res. (1999) 19(5)3675–3680.
   Google Scholar
• SHAH BH, NAWAZ Z, PERTANI SA et al: Inhibitory effectof curcumin, a food spice from turmeric, on platelet-activating factor- and arachidonic acid-mediated platelet aggregation through inhibition of thromboxane formation and Ca2+ signaling. Biochem. Pharmacol. (1999) 58(7):1167–1172.
   PubMed Web of Science ®Google Scholar
• GUPTA B, GHOSH B: Curcuma longa inhibits TNF-alpha induced expression of adhesion molecules on human umbilical vein endothelial cells. Int. J. Immunopharmacol. (1999) 21(10:745–757.
   PubMedGoogle Scholar
• JOBIN C, BRADHAM CA, RUSSO MP et al. Curcumin cytokine-mediated NF-kappa B activation and proinflammatory gene expression by inhibiting inhibitory Factor I-kappa B kinase activity. J. Immunol. (1999) 163(6):3474–3483.
   PubMed Web of Science ®Google Scholar
• ABE Y, HASHIMOTO S, HORIE T: Curcumin inhibition ofinflammatory cytokine production by human periph-eral blood monocytes and alveolar macrophages. Pharmacol. Res. (1999) 39(0:41–47.
   PubMedGoogle Scholar
• ZHANG F, ALTORKI NK, MESTRE JR, SUBBARAMAIAH K,DANNENBERG AJ: Curcumin inhibits cyclooxygenase-2 transcription in bile acid- and phorbol ester-treated human gastrointestinal epithelial cells. Carcinogenesis (1999) 20(3):445–451.
   PubMed Web of Science ®Google Scholar
• SELIM S, HARNAGEL RE, OSIMITZ TG, GABRIEL KL,SCHOENIG GP: Absorption, metabolism and excretion of N,N-diethyl-m- toluamide following dermal applica-tion to human volunteers. Fundam. Appl. Toxicol. (1995) 25:95–100.
   PubMedGoogle Scholar
• LIPSCOMB JW, KRAMER JE, LEIKIN JB: Seizure following brief exposure to the insect repellent N,N-diethyl-m-toluamide. Ann. Emerg. Med. (1992) 21:315–317.
   PubMed Web of Science ®Google Scholar
• SOLOMON KD, TURKALJ JW, WHITESIDE SB, STEWART JA, APPLE DJ: Topical 0.5% ketorolac vs. 0.03% flurbi-profen for inhibition of miosis during cataract surgery. Arch. Ophthalmol (1997) 115(9):1119–1122.
   Google Scholar
• JONES DS, IRWIN CR, WOOLFSON AD, DJOKIC J, ADAMS: Physicochemical characterization and preliminary in vivo efficacy of bioadhesive, semisolid formulations containing flurbiprofen for the treatment of gingivitis. Pharma. Sci. (1999) 88(6):592–598.
   PubMed Web of Science ®Google Scholar
• RICHETER-HINTZ, SCHUPPE HC, HOMEY B, LEHMANN P, RUZICKA T: Topical tacrolimus (FK 506) is effective in the treatment of peoderma gangrenosum. J. Am. Acad. Dermatol. (2000) 42(2)304–305.
   Google Scholar
• FLEISCHER AB, JR.: Treatment of atopic dermatitis: role of tacrolimus ointment as a topical noncorticoster-oidal therapy. J. Allergy Clin. Immunol. (1999) 104 (3):S126–130.
   Google Scholar
• BIEBER T: Topical tacrolimus (FK506): a new milestone in the management of atopic dermatitis. J. Allergy Clin. Immunol. (1998) 102(4):555–557.
   PubMed Web of Science ®Google Scholar
• RIVIERE JE, HEIT MC: Electrically-assisted transdermal drug delivery. Pharma. Res. (1997) 14(6):687–697.
   Google Scholar
• BANGA AK, BOSE S, GHOSH TK: Iontophoresis and electroporation: comparisons and contrasts. Int. J. Pharmaceutics (1999) 179:1–19.
   PubMed Web of Science ®Google Scholar
• GULATI M, GROVER M, SINGH S, SINGH M: Lipophilic drug derivatives in liposomes. Int. J. Pharmaceutics (1998) 165:129–168.
   Web of Science ®Google Scholar
• CARLOTTI ME, GALLARATE M, MOREL S, UGAZIO E: Micellar solutions and microemulsions of ordorous molecules. J. Cosmetic ScL (1999) 50:281–295.
   Web of Science ®Google Scholar
• PATRICK Al, BEALL HD, GILROY P, SLOAN KB: Effect ofvehicles on topical delivery of 5-fluorouracil (5FU) by 1-acy1-5FU prodrugs. Int. J. Pharmaceutics (1997) 154:39–48.
   Web of Science ®Google Scholar